Promising Outlook for Axsome Therapeutics Driven by Auvelity’s Strong Market Performance and Growth Prospects
Morgan Stanley analyst Vikram Purohit maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report) yesterday and set a price target ...
bovnews14h
How Does Dyne Therapeutics Inc (DYN) Stack Up Against Its Industry Peers?
Dyne Therapeutics Inc (DYN) stock saw a modest uptick, ending the day at $13.72 which represents a slight increase of $0.03 or 0.22% from the prior close of $13.69. The stock opened at $13.72 and ...
Now's the time to invest beyond U.S. stocks and bonds: Morgan Stanley's top wealth manager
A return to U.S. stock and bond prices moving together is a key reason why investors should curb equity risk by buying other assets such as commodities, Morgan Stanley Wealth Management said this week ...
Indiatimes2h
Forex News
Around 23 midcap mutual funds (MFs) outperformed their benchmarks in the past year, reflecting a 79% outperformance rate. Only six schemes lagged behind their benchmarks. For example, Aditya Birla SL ...